Race Oncology Welcomes New Director and Shareholder

Race Oncology Ltd. (AU:RAC) has released an update.

Race Oncology Ltd has announced the appointment of Dr. Daniel Tillett as a director, effective from September 1, 2024. Dr. Tillett’s initial director’s interest notice reveals significant holdings, including over 17 million fully paid ordinary shares and various options with expiry dates ranging from 2025 to 2028. No interests in securities were reported where Dr. Tillett is not the registered holder, and no director’s interests in contracts were disclosed.

For further insights into AU:RAC stock, check out TipRanks’ Stock Analysis page.